ReviewOchsner journal2026
Efficacy and Safety of the iStent infinite Trabecular Micro-Bypass Device for Glaucoma: A Systematic Review and Meta-Analysis.
Review in Ochsner journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The iStent infinite (Glaukos Corporation) is a third-generation trabecular micro-bypass device approved for stand-alone use in patients with inadequately controlled open-angle glaucoma, but overall efficacy and safety estimates have not been quantitatively synthesized via meta-analysis. Our objective was to evaluate the 12-month efficacy and safety of iStent infinite device implantation by examining intraocular pressure reduction and glaucoma medication reduction. Methods: We conducted a systematic review and meta-analysis per the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines after registering the review protocol with the International Prospective Register of Systematic Reviews (PROSPERO). We searched PubMed/MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov from inception through November 2025 for studies reporting 12-month outcomes after iStent infinite device implantation (stand-alone or combined with phacoemulsification). Pooled mean changes in intraocular pressure and medications were calculated, heterogeneity was assessed with I Results: Three nonrandomized studies comprising 199 eyes with 12-month follow-up were included. The pooled mean intraocular pressure reduction at 12 months was 4.48 mm Hg (95% CI 3.04 to 5.92; Conclusion: iStent infinite device implantation was associated with clinically meaningful 12-month reductions in intraocular pressure, a modest reduction in medication burden, and a favorable short-term safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.